← All trials
NCT05018013
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 21, 2021
- Primary completion
- Aug 1, 2022
- Completion date
- Dec 30, 2022
- First posted
- Aug 24, 2021
- Last posted
- Nov 12, 2021
- Enrollment
- 240
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Shijiazhuang Pharma Group (CSPC)Lead sponsor
- Jiao Tong UniversityStudy chair
- Shijiazhuang Pharma Group (CSPC)Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.